INFU News & Events

InfuSystem announced that the company's Board of Directors has approved a stock repurchase program authorizing the company to repurchase up to $20M of the company's outstanding common stock starting on July 1, 2026 and running through June 30, 2028. The program will supersede the previous authorization which is set to expire on June 30, 2026. Under the current authorization, the company repurchased approximately 1.6M shares of stock for approximately $11.9M though March 31, 2026. Repurchases will be made through open market purchases, private transactions, or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934. Carrie Lachance, Chief Executive Officer of InfuSystem, said, "This authorization carries on the Company's established buyback policy which we have used when appropriate to enhance shareholder value. I believe the stock repurchase program demonstrates our confidence in being able to continue to execute with discipline, deliver profitable growth and drive long term value for the rest of 2026 and beyond. It also reflects the strength of our balance sheet and cash flows. Our top priority for use of capital remains making strategic investments that position the Company for sustainable growth, although this program provides us with the flexibility to be opportunistic in repurchasing shares when valuations become attractive."

Reports Q1 revenue $33.7M, consensus $34.35M. CEO Carrie Lachance commented, "Overall, we delivered a solid quarter that reflects both disciplined execution and meaningful strategic progress. While GAAP revenue declined modestly year over year to $33.7M, that decline was expected and resulted from the strategic decision to restructure our GE Healthcare biomedical services contract. On a pro-forma basis, net revenue grew 1.7%, and just as importantly, profitability held strong. We delivered $6.4M of Adjusted EBITDA, essentially flat year over year, due to margins improving to 18.9%. The restructuring reduced Q1 revenue by $1.6M, but it enabled a significantly larger reduction in direct contract expenses. While GAAP revenue is lower, the economics of the business are better, and that's clearly showing up in our Adjusted EBITDA performance. On March 1, 2026, after nearly two years of intense preparation, we successfully went live on our new ERP system. I would call this transformational...the ERP gives us a scalable platform to support future growth. We're already identifying enhancements that offer fast payback and high returns."